Day2, July 6, 12:30 p.m., Session B:
The bavarian therapeutic strategy to combat the COVID 19 pandemic
Carsten Rudolph, CEO and president, pharmacist by training, received his PhD from the Department of Pharmacy of the FU Berlin. Since 2003 he is group leader at the Dr. von Haunerschen Kinderspital of the Ludwig Maximilians University, Munich. He is lead inventor of the SNIM® RNA-Technology and co-inventor of numerous drug delivery patent applications. Carsten Rudolph received his post-doctoral lecture qualification at the Department of Pharmacy, FU Berlin in 2009. In 2005 Carsten Rudolph received the prestigious BioFuture Award of the BMBF which is the highest endowed young investigator award in Germany.
Copyright © 2022 BioM Biotech Cluster Development GmbH
Alle Rechte vorbehalten